The Nasopharyngeal Carcinoma market size is anticipated to increase during the study period (2018-30) in the 7MM

 Breaking News
  • No posts were found

The Nasopharyngeal Carcinoma market size is anticipated to increase during the study period (2018-30) in the 7MM

December 23
16:42 2021
The Nasopharyngeal Carcinoma market size is anticipated to increase during the study period (2018-30) in the 7MM
Nasopharyngeal Carcinoma Market
The expansion of R&D activities and the development of targeted therapies will aid in the growth of the R/M-NPC market.

DelveInsight’s Nasopharyngeal Carcinoma market report thoroughly explains the Nasopharyngeal Carcinoma historical and forecasted epidemiology and the Nasopharyngeal Carcinoma market trends in the 7MM. 

Some of the Important Findings from the Nasopharyngeal Carcinoma Market Report

  • According to the National Health Service (NHS), nasopharyngeal cancer affects men three times more than women.
  • According to Globocan data, about 133,354 persons were affected by nasopharyngeal cancer worldwide in 2020, with the United States accounting for 1,898 incident cases.
  • Leading players in the Nasopharyngeal Carcinoma market include BieGene, Atara Biotherapeutics, Novartis Pharmaceuticals, Junshi Biosciences, Coherus, Harbour BioMed, and others.
  • Key Nasopharyngeal Carcinoma therapies in the pipeline include Tislelizumab, Tabelecleucel plus Keytruda, PDR001, Toripalimab, HBM9167, and others.
  • The FDA has granted Toripalimab (Junshi Biosciences/Coherus) as Breakthrough Therapy Designation for Nasopharyngeal Carcinoma treatment.
  • The FDA has granted HBM9167 (Harbour BioMed) as Orphan Drug Designation for the Nasopharyngeal Carcinoma treatment.

Request for a sample to know more @ Nasopharyngeal Carcinoma Treatment Outlook

Nasopharyngeal Carcinoma: Overview

Nasopharyngeal cancer affects the portion of the throat that connects the back of the nose to the back of the mouth (nasopharynx). It’s important to distinguish it from other cancers that affect the throat, such as laryngeal cancer and esophageal cancer.

Nasopharyngeal Carcinoma Epidemiology Segmentation

The Nasopharyngeal Carcinoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Nasopharyngeal Carcinoma Total Incidence 
  • Nasopharyngeal Carcinoma Gender-Specific Incidence 
  • Nasopharyngeal Carcinoma Age-Specific Incidence
  • Nasopharyngeal Carcinoma Stage-Wise Incidence
  • Recurrent/Metastatic Nasopharyngeal Carcinoma Incidence 
  • Nasopharyngeal Carcinoma Treated Pool

Nasopharyngeal Carcinoma Treatment Landscape 

Radiation therapy is the most common treatment for nasopharyngeal cancer. On the other hand, surgery is sometimes performed to remove lymph nodes after chemo-radiotherapy or to treat nasopharyngeal cancer that has returned after the first treatment.

There is just one targeted medication, cetuximab (Erbitux), used to treat nasopharyngeal cancer. However, its specific role in treating nasopharyngeal cancer is still being researched. Pembrolizumab (Keytruda) and nivolumab (Opdivo) are two other treatments utilized to treat nasopharyngeal carcinoma.

Nasopharyngeal Carcinoma Market Outlook

The expansion of R&D activities and the development of targeted therapies will aid in the growth of the R/M-NPC market.

The anticipated release of TT10, Toripalimab, and other drugs to treat recurrent or metastatic Nasopharyngeal Carcinoma (R/M-NPC) will drive market growth in the coming years.

Get a detailed analysis of the market @ Nasopharyngeal Carcinoma Market Analysis

Nasopharyngeal Carcinoma Pipeline Therapies and Key Companies 

  • Tislelizumab: BieGene
  • Tabelecleucel plus Keytruda: Atara Biotherapeutics
  • PDR001: Novartis Pharmaceuticals
  • Toripalimab: Junshi Biosciences/Coherus
  • HBM9167: Harbour BioMed 

Table of Contents

1.

Report Introduction

2.

Executive Summary

3.

SWOT analysis

4.

Nasopharyngeal Carcinoma (NPC): Patient Share (%) Overview at a Glance

5.

Nasopharyngeal Carcinoma (NPC): Market Overview at a Glance

6.

Disease Background and Overview 

7.

Epidemiology and Patient Population

8.

Country-Specific Patient Population of Nasopharyngeal Cancer 

9.

Current Treatment and Medical Practices

10.

Unmet Needs

11.

Emerging Therapies

12.

Nasopharyngeal Carcinoma (NPC): Market Outlook

13.

Market Access and Reimbursement of Therapies

14.

Market drivers

15.

Market barriers

16.

Appendix

17.

Report Methodology

18

Sources Used

19.

DelveInsight Capabilities

20.

Disclaimer

21.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Nasopharyngeal Neoplasms Market

DelveInsight’s “Nasopharyngeal Neoplasms – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Nasopharyngeal Neoplasms, historical and forecasted epidemiology as well as the Nasopharyngeal Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/